Initiating antiplatelet therapy in diabetes: A PCO view

British Journal of Diabetes and Vascular Disease

Volumn 3, Issue 5, 2003, Pages 349-353

  Morrell, Jonathan ^a  

^a St Leonards on Sea   (United Kingdom)

Author keywords

Aspirin; Clopidogrel; Diabetes; Platelets; Vascular disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; PLACEBO;

BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DISEASE SEVERITY; DRUG USE; EVIDENCE BASED MEDICINE; HEALTH CARE ORGANIZATION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; PATIENT CARE; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; STROKE;

EID: 0242319789     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514030030050701     Document Type: Review

References (31)

1. Rayner M, Petersen S, Buckley C, Press V. Coronary Heart Disease Statistics: Diabetes Supplement. London: British Heart Foundation, 2001.
2. Diabetes UK. Fact sheet no. 3 - diabetes: cost and complications. http://www.diabetes.org.uk/infocentre/fact/fact3.htm
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
4. Evans JMM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross-sectional and cohort studies. BMJ 2002;324:939-42.
5. Jorgensen H, Nakayama H, Raaschou HO, Olsen TS. Stroke in patients with diabetes. The Copenhagen Stroke Study. Stroke 1994;25:1977-84.
6. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001;85:265-71.
7. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
8. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
9. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002;136:157-60.
10. Pearson TA, Blair SN, Daniels SR et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus Panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002;106:388-91.
11. Scottish Intercollegiate Guidelines Network. Guideline 55: Management of Diabetes. Edinburgh: SIGN, 2001. www.sign.ac.uk/guidelines/fulltext/55
12. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434-503.
13. Wood D, Durrington P, Poulter N et al. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(suppl 2):S1-S29.
14. Bhatt DL, Marso SP, Hirsch AT et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90:625-8.
15. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287: 2570-81.
16. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in Type 2 diabetes. Diabetes Care 2001;24:1476-85.
17. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
18. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
19. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2000;23(suppl 1):S33-S49.
20. Smith Jr SC, Blair SN, Bonow RO et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001;104:1577-9.
21. Braunwald E, Antman EM, Beasley JW et al. Management of Patients with Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction Update. ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). http://www.acc.org/clinical/guidelines/unstable/incorporated/index.htm
22. Scottish Intercollegiate Guidelines Network. Guideline No. 36. Antithrombotic Therapy. Edinburgh: SIGN, 1999.www.sign.ac.uk/guidelines/fulltext/36
23. Anticoagulants, antithrombotics and fibrinolytics: Asasantin retard and Persantin retard. MIMS 2002;July:Section 2F.
24. Diener HC, Cunha L, Forbes S et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
25. Bertrand ME. Press conference press release: Guidelines of the European Society of Cardiology concerning acute coronary syndromes without ST-segment elevation. http://www.escardio.org/VPO/pcdetails/FSC%20Guidelines/PC%20Bertrand.pdf
26. Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand. 1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. N Z Med J 1996;109:224-31.
27. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991;121:293-8.
28. Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci 2001;101:671-9 (erratum in Clin Sci 2002;102:679).
29. Testing Times: A Review of Diabetes Services in England and Wales. London: The Audit Commission, 2001.
30. Department of Health. National Service Framework for Diabetes. London: Stationery Office, 2003. www.doh.gov.uk/nsf/diabetes/
31. Department of Health. National Service Framework for Coronary Heart Disease. London: Stationery Office, 2000. www.doh.gov.uk/nsf/coronary/